ID   BCCIP_HUMAN             Reviewed;         314 AA.
AC   Q9P287; B3KP45; Q8ND15; Q96GC4; Q9P288;
DT   19-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   18-JUN-2025, entry version 182.
DE   RecName: Full=BRCA2 and CDKN1A-interacting protein;
DE   AltName: Full=P21- and CDK-associated protein 1;
DE   AltName: Full=Protein TOK-1;
GN   Name=BCCIP; Synonyms=TOK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, INTERACTION WITH
RP   CDKN1A, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Brain;
RX   PubMed=10878006; DOI=10.1074/jbc.m003031200;
RA   Ono T., Kitaura H., Ugai H., Murata T., Yokoyama K.K., Iguchi-Ariga S.M.M.,
RA   Ariga H.;
RT   "TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-
RT   dependent inhibitory activity toward CDK2 kinase.";
RL   J. Biol. Chem. 275:31145-31154(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=12527204; DOI=10.1016/s0378-1119(02)01098-3;
RA   Meng X., Liu J., Shen Z.;
RT   "Genomic structure of the human BCCIP gene and its expression in cancer.";
RL   Gene 302:139-146(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH BRCA2, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11313963; DOI=10.1038/sj.onc.1204098;
RA   Liu J., Yuan Y., Huan J., Shen Z.;
RT   "Inhibition of breast and brain cancer cell growth by BCCIPalpha, an
RT   evolutionarily conserved nuclear protein that interacts with BRCA2.";
RL   Oncogene 20:336-345(2001).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH CDKN1A.
RX   PubMed=14726710;
RA   Meng X., Liu J., Shen Z.;
RT   "Inhibition of G1 to S cell cycle progression by BCCIP beta.";
RL   Cell Cycle 3:343-348(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=15539944; DOI=10.4161/cc.3.11.1213;
RA   Meng X., Lu H., Shen Z.;
RT   "BCCIP functions through p53 to regulate the expression of p21Waf1/Cip1.";
RL   Cell Cycle 3:1457-1462(2004).
RN   [10]
RP   FUNCTION, INTERACTION WITH BRCA2, AND SUBCELLULAR LOCATION.
RX   PubMed=15713648; DOI=10.1128/mcb.25.5.1949-1957.2005;
RA   Lu H., Guo X., Meng X., Liu J., Allen C., Wray J., Nickoloff J.A., Shen Z.;
RT   "The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus
RT   formation and homologous recombinational repair.";
RL   Mol. Cell. Biol. 25:1949-1957(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=17947333; DOI=10.1093/nar/gkm732;
RA   Lu H., Yue J., Meng X., Nickoloff J.A., Shen Z.;
RT   "BCCIP regulates homologous recombination by distinct domains and
RT   suppresses spontaneous DNA damage.";
RL   Nucleic Acids Res. 35:7160-7170(2007).
RN   [13]
RP   INTERACTION WITH MTDH.
RX   PubMed=18440304; DOI=10.1016/j.bbrc.2008.04.084;
RA   Ash S.C., Yang D.Q., Britt D.E.;
RT   "LYRIC/AEG-1 overexpression modulates BCCIPalpha protein levels in prostate
RT   tumor cells.";
RL   Biochem. Biophys. Res. Commun. 371:333-338(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-112, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   INTERACTION WITH TENT5C.
RX   PubMed=28931820; DOI=10.1038/s41467-017-00578-5;
RA   Mroczek S., Chlebowska J., Kulinski T.M., Gewartowska O., Gruchota J.,
RA   Cysewski D., Liudkovska V., Borsuk E., Nowis D., Dziembowski A.;
RT   "The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in
RT   multiple myeloma.";
RL   Nat. Commun. 8:619-619(2017).
RN   [20]
RP   FUNCTION, INTERACTION WITH DCTN1; ACTR1A AND TUBULINS, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=28394342; DOI=10.1038/onc.2017.92;
RA   Huhn S.C., Liu J., Ye C., Lu H., Jiang X., Feng X., Ganesan S., White E.,
RA   Shen Z.;
RT   "Regulation of spindle integrity and mitotic fidelity by BCCIP.";
RL   Oncogene 36:4750-4766(2017).
CC   -!- FUNCTION: During interphase, required for microtubule organizing and
CC       anchoring activities. During mitosis, required for the organization and
CC       stabilization of the spindle pole (PubMed:28394342). Isoform 2/alpha is
CC       particularly important for the regulation of microtubule anchoring,
CC       microtubule stability, spindle architecture and spindle orientation,
CC       compared to isoform 1/beta (PubMed:28394342). May promote cell cycle
CC       arrest by enhancing the inhibition of CDK2 activity by CDKN1A. May be
CC       required for repair of DNA damage by homologous recombination in
CC       conjunction with BRCA2. May not be involved in non-homologous end
CC       joining (NHEJ). {ECO:0000269|PubMed:10878006,
CC       ECO:0000269|PubMed:14726710, ECO:0000269|PubMed:15539944,
CC       ECO:0000269|PubMed:15713648, ECO:0000269|PubMed:17947333,
CC       ECO:0000269|PubMed:28394342}.
CC   -!- SUBUNIT: Interacts with BRCA2, CDKN1A and MTDH/LYRIC (PubMed:10878006,
CC       PubMed:11313963, PubMed:14726710, PubMed:15713648, PubMed:18440304).
CC       Isoform 2/alpha, but not isoform 1/beta, interacts with DCTN1/p150-
CC       glued and ACTR1A/ARP1 (PubMed:28394342). Both isoform 1 and isoform 2
CC       interact with alpha-, beta- and gamma-tubulins (PubMed:28394342).
CC       Interacts with TENT5C; the interaction has no effect on TENT5C poly(A)
CC       polymerase function (PubMed:28931820). {ECO:0000269|PubMed:10878006,
CC       ECO:0000269|PubMed:11313963, ECO:0000269|PubMed:14726710,
CC       ECO:0000269|PubMed:15713648, ECO:0000269|PubMed:18440304,
CC       ECO:0000269|PubMed:28394342, ECO:0000269|PubMed:28931820}.
CC   -!- INTERACTION:
CC       Q9P287; Q9HC77: CENPJ; NbExp=3; IntAct=EBI-711154, EBI-946194;
CC       Q9P287; Q9Y324: FCF1; NbExp=3; IntAct=EBI-711154, EBI-5455734;
CC       Q9P287; P82933: MRPS9; NbExp=3; IntAct=EBI-711154, EBI-721385;
CC       Q9P287; P01127: PDGFB; NbExp=3; IntAct=EBI-711154, EBI-1554925;
CC       Q9P287; Q53GL6: RALY; NbExp=3; IntAct=EBI-711154, EBI-9512693;
CC       Q9P287; P62829: RPL23; NbExp=8; IntAct=EBI-711154, EBI-353303;
CC       Q9P287; P63173: RPL38; NbExp=3; IntAct=EBI-711154, EBI-359141;
CC       Q9P287; P52744: ZNF138; NbExp=3; IntAct=EBI-711154, EBI-10746567;
CC       Q9P287; P17023: ZNF19; NbExp=3; IntAct=EBI-711154, EBI-12884200;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10878006,
CC       ECO:0000269|PubMed:11313963, ECO:0000269|PubMed:15713648}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome, centriole
CC       {ECO:0000269|PubMed:28394342}. Cytoplasm, cytoskeleton, spindle pole
CC       {ECO:0000269|PubMed:28394342}. Note=Colocalizes with BRCA2 in discrete
CC       nuclear foci (PubMed:15713648). In interphase, preferential localizes
CC       to the mother centriole (PubMed:28394342). Recruited to the spindle
CC       pole matrix and centrosome by microtubules and dynein/dynactin activity
CC       (PubMed:28394342). {ECO:0000269|PubMed:15713648,
CC       ECO:0000269|PubMed:28394342}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:28394342}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000269|PubMed:28394342}. Note=Isoform
CC       1/beta tends to be less abundant at, and less strongly associated with,
CC       centrosomes than isoform 2/alpha. {ECO:0000269|PubMed:28394342}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:28394342}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000269|PubMed:28394342}. Note=Isoform
CC       2/alpha tends to be more abundant at, and more strongly associated
CC       with, centrosomes than isoform 1/beta. {ECO:0000269|PubMed:28394342}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Beta;
CC         IsoId=Q9P287-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=Q9P287-2; Sequence=VSP_020540;
CC       Name=3;
CC         IsoId=Q9P287-3; Sequence=VSP_020541;
CC       Name=4;
CC         IsoId=Q9P287-4; Sequence=VSP_042023;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in testis and skeletal
CC       muscle and at lower levels in brain, heart, kidney, liver, lung, ovary,
CC       pancreas, placenta, and spleen. {ECO:0000269|PubMed:10878006,
CC       ECO:0000269|PubMed:11313963}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is expressed throughout the cell cycle.
CC       Isoform 2 is expressed following mitosis and peaks in the G1/S phase of
CC       the cell cycle. {ECO:0000269|PubMed:10878006}.
CC   -!- MISCELLANEOUS: HT1080 cells that constitutively express low levels of
CC       BCCIP display increased levels of spontaneous single-stranded DNA and
CC       double-strand breaks.
CC   -!- SIMILARITY: Belongs to the BCP1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB040450; BAA92927.1; -; mRNA.
DR   EMBL; AB040451; BAA92928.1; -; mRNA.
DR   EMBL; AY064247; AAL55436.1; -; Genomic_DNA.
DR   EMBL; AY064247; AAL55438.1; -; Genomic_DNA.
DR   EMBL; AY064248; AAL55439.1; -; mRNA.
DR   EMBL; AY064249; AAL55440.1; -; mRNA.
DR   EMBL; AK055691; BAG51557.1; -; mRNA.
DR   EMBL; AL834458; CAD39118.1; -; mRNA.
DR   EMBL; AL360176; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009771; AAH09771.1; -; mRNA.
DR   CCDS; CCDS7649.1; -. [Q9P287-2]
DR   CCDS; CCDS7650.1; -. [Q9P287-4]
DR   CCDS; CCDS7651.1; -. [Q9P287-1]
DR   RefSeq; NP_057651.1; NM_016567.4. [Q9P287-2]
DR   RefSeq; NP_510868.1; NM_078468.3. [Q9P287-1]
DR   RefSeq; NP_510869.1; NM_078469.3. [Q9P287-4]
DR   PDB; 7KYQ; X-ray; 3.06 A; A=61-314.
DR   PDB; 7KYS; X-ray; 2.20 A; A/B/C=61-314.
DR   PDB; 8EQB; EM; 6.50 A; C/F/I/L=50-259.
DR   PDB; 8EXE; X-ray; 3.50 A; B=50-259.
DR   PDB; 8EXF; X-ray; 3.22 A; B=50-237.
DR   PDBsum; 7KYQ; -.
DR   PDBsum; 7KYS; -.
DR   PDBsum; 8EQB; -.
DR   PDBsum; 8EXE; -.
DR   PDBsum; 8EXF; -.
DR   AlphaFoldDB; Q9P287; -.
DR   SMR; Q9P287; -.
DR   BioGRID; 121161; 158.
DR   CORUM; Q9P287; -.
DR   FunCoup; Q9P287; 2804.
DR   IntAct; Q9P287; 56.
DR   MINT; Q9P287; -.
DR   STRING; 9606.ENSP00000357748; -.
DR   GlyGen; Q9P287; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9P287; -.
DR   PhosphoSitePlus; Q9P287; -.
DR   BioMuta; BCCIP; -.
DR   DMDM; 74753124; -.
DR   jPOST; Q9P287; -.
DR   MassIVE; Q9P287; -.
DR   PaxDb; 9606-ENSP00000357748; -.
DR   PeptideAtlas; Q9P287; -.
DR   ProteomicsDB; 83752; -. [Q9P287-1]
DR   ProteomicsDB; 83753; -. [Q9P287-2]
DR   ProteomicsDB; 83754; -. [Q9P287-3]
DR   ProteomicsDB; 83755; -. [Q9P287-4]
DR   Pumba; Q9P287; -.
DR   Antibodypedia; 32428; 157 antibodies from 28 providers.
DR   DNASU; 56647; -.
DR   Ensembl; ENST00000278100.11; ENSP00000278100.6; ENSG00000107949.17. [Q9P287-1]
DR   Ensembl; ENST00000299130.7; ENSP00000299130.3; ENSG00000107949.17. [Q9P287-4]
DR   Ensembl; ENST00000368759.5; ENSP00000357748.5; ENSG00000107949.17. [Q9P287-2]
DR   GeneID; 56647; -.
DR   KEGG; hsa:56647; -.
DR   MANE-Select; ENST00000278100.11; ENSP00000278100.6; NM_078468.3; NP_510868.1.
DR   UCSC; uc001ljb.5; human. [Q9P287-1]
DR   AGR; HGNC:978; -.
DR   CTD; 56647; -.
DR   DisGeNET; 56647; -.
DR   GeneCards; BCCIP; -.
DR   HGNC; HGNC:978; BCCIP.
DR   HPA; ENSG00000107949; Low tissue specificity.
DR   MIM; 611883; gene.
DR   OpenTargets; ENSG00000107949; -.
DR   VEuPathDB; HostDB:ENSG00000107949; -.
DR   eggNOG; KOG3034; Eukaryota.
DR   GeneTree; ENSGT00390000000696; -.
DR   HOGENOM; CLU_068770_1_1_1; -.
DR   InParanoid; Q9P287; -.
DR   OMA; VKFYRKE; -.
DR   OrthoDB; 27543at2759; -.
DR   PAN-GO; Q9P287; 1 GO annotation based on evolutionary models.
DR   PhylomeDB; Q9P287; -.
DR   PathwayCommons; Q9P287; -.
DR   SignaLink; Q9P287; -.
DR   BioGRID-ORCS; 56647; 419 hits in 1167 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; BCCIP; human.
DR   GeneWiki; BCCIP; -.
DR   GenomeRNAi; 56647; -.
DR   Pharos; Q9P287; Tbio.
DR   PRO; PR:Q9P287; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q9P287; protein.
DR   Bgee; ENSG00000107949; Expressed in ventricular zone and 200 other cell types or tissues.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB.
DR   GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0019207; F:kinase regulator activity; IDA:MGI.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IMP:UniProtKB.
DR   GO; GO:0034453; P:microtubule anchoring; IMP:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0090307; P:mitotic spindle assembly; IMP:UniProtKB.
DR   GO; GO:0007052; P:mitotic spindle organization; IMP:UniProtKB.
DR   GO; GO:0061101; P:neuroendocrine cell differentiation; IDA:UniProtKB.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:MGI.
DR   InterPro; IPR025602; BCP1_family.
DR   PANTHER; PTHR13261; BRCA2 AND CDKN1A INTERACTING PROTEIN; 1.
DR   PANTHER; PTHR13261:SF0; BRCA2 AND CDKN1A-INTERACTING PROTEIN; 1.
DR   Pfam; PF13862; BCCIP; 1.
DR   PIRSF; PIRSF028983; BCP1; 1.
DR   neXtProt; NX_Q9P287; -.
DR   PharmGKB; PA25290; -.
DR   TreeFam; TF320301; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cytoplasm; Cytoskeleton;
KW   DNA damage; DNA repair; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome.
FT   CHAIN           1..314
FT                   /note="BRCA2 and CDKN1A-interacting protein"
FT                   /id="PRO_0000249687"
FT   REGION          1..56
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          59..167
FT                   /note="Interaction with BRCA2"
FT   REGION          161..259
FT                   /note="Interaction with CDKN1A"
FT   COMPBIAS        25..56
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         112
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CWI3"
FT   VAR_SEQ         259..314
FT                   /note="KAILKFNYSVQEESDTCLGGKWSFDDVPMTPLRTVMLIPGDKMNEIMDKLKE
FT                   YLSV -> EQGKPEVLGGPDTRRGLEPVPIQHNGGSRGQVTALVSLKAGLIQSRSTLSD
FT                   FQGTFMTVGIALS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10878006,
FT                   ECO:0000303|PubMed:12527204"
FT                   /id="VSP_020540"
FT   VAR_SEQ         259..314
FT                   /note="KAILKFNYSVQEESDTCLGGKWSFDDVPMTPLRTVMLIPGDKMNEIMDKLKE
FT                   YLSV -> EQGKPEVLGGPDTRRGLEPVPIQHNGWSVPPVLE (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042023"
FT   VAR_SEQ         285..314
FT                   /note="VPMTPLRTVMLIPGDKMNEIMDKLKEYLSV -> WSVPPVLE (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_020541"
FT   VARIANT         254
FT                   /note="E -> Q (in dbSNP:rs17153610)"
FT                   /id="VAR_046642"
FT   CONFLICT        75
FT                   /note="K -> R (in Ref. 3; BAG51557)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        230
FT                   /note="G -> E (in Ref. 6; AAH09771)"
FT                   /evidence="ECO:0000305"
FT   STRAND          61..64
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           68..70
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           71..82
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           89..98
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   TURN            99..102
FT                   /evidence="ECO:0007829|PDB:7KYQ"
FT   STRAND          104..108
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          126..132
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   TURN            133..138
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           140..156
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           159..169
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          172..174
FT                   /evidence="ECO:0007829|PDB:7KYQ"
FT   STRAND          176..183
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           189..191
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           192..208
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           212..214
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          217..227
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          247..250
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           253..259
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          261..267
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   STRAND          288..297
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           298..300
FT                   /evidence="ECO:0007829|PDB:7KYS"
FT   HELIX           301..312
FT                   /evidence="ECO:0007829|PDB:7KYS"
SQ   SEQUENCE   314 AA;  35979 MW;  203CA32F7BE0A806 CRC64;
     MASRSKRRAV ESGVPQPPDP PVQRDEEEEK EVENEDEDDD DSDKEKDEED EVIDEEVNIE
     FEAYSLSDND YDGIKKLLQQ LFLKAPVNTA ELTDLLIQQN HIGSVIKQTD VSEDSNDDMD
     EDEVFGFISL LNLTERKGTQ CVEQIQELVL RFCEKNCEKS MVEQLDKFLN DTTKPVGLLL
     SERFINVPPQ IALPMYQQLQ KELAGAHRTN KPCGKCYFYL LISKTFVEAG KNNSKKKPSN
     KKKAALMFAN AEEEFFYEKA ILKFNYSVQE ESDTCLGGKW SFDDVPMTPL RTVMLIPGDK
     MNEIMDKLKE YLSV
//
